Harold S. Geneen, formerly chairman of the board of directorsof ITT Corp., has been appointed to the board of Ivax Corp. ofMiami. Geneen is on the board of trustees of the Salk Instituteand the board of governors of the School of Medicine of theUniversity of Miami. Ivax (AMEX:IVX) is a holding companywith subsidiaries in specialty chemicals, pharmaceuticals andmedical diagnostics.

Nova Pharmaceutical Corp. of Baltimore has named Michael J.Demchuk Jr. vice president and chief financial officer andVincent L. Fabiano assistant vice president and corporatesecretary. Demchuk had been vice president of administrationand control; Fabiano was chief patent counsel. Nova(NASDAQ:NOVX) is focused on inflammation, central nervoussystem disorders and drug delivery.

Joseph L. Turner has been named vice president of businessdevelopment and chief financial officer of Cortech Inc. ofDenver. He was chairman and chief financial officer of Eli Lillyand Co.'s Swiss subsidiary. Privately held Cortech is developingtreatments for inflammatory and autoimmune diseases andallergies.

TheraTech Inc. of Salt Lake City has named Deborah A.Eppstein vice president of corporate planning. She had beendirector of business development, biotechnology and drugdelivery for Syntex Corp. TheraTech is developing controlledrelease drug delivery technologies.

Belmac Corp. of Tampa, Fla., has named Dr. Robert M. Stote vicepresident and chief science officer of the corporation andpresident of its Belmac Institute for Medical Research Inc. Stotewas senior vice president and medical director of worldwidemedical affairs at SmithKline Beecham. Vittorio Ferraris hasbeen named vice president of worldwide businessdevelopment. He had been senior vice president,intercontinental, for Bristol-Myers Squibb Corp. Belmac(AMEX:BLM) is developing antibiotics and other pharmaceuticalproducts.

Vertex Pharmaceuticals Inc. of Cambridge, Mass., has namedMark Carthy director of business development. Carthy hadmanaged Millipore Inc.'s worldwide chemical filtrationbusiness. Vertex (NASDAQ: VRTX) focuses on structure-basedrational drug design.

Genetic Therapy Inc. of Gaithersburg, Md., has named to itsboard of directors Jacques F. Rejeange, president and chiefexecutive of Sandoz Pharmaceuticals Corp. Genetic Therapy(NASDAQ:GTII) is developing delivery systems for human genetherapy for genetic and acquired diseases.

(c) 1997 American Health Consultants. All rights reserved.